Core Viewpoint - Gilead Sciences reported a 5% year-over-year revenue growth in Q4, reaching $7.9 billion, surpassing analyst expectations of $7.7 billion [1] - The adjusted earnings per share (EPS) of $1.86 also exceeded the forecast of $1.81 [1] Group 1: Financial Performance - Q4 revenue increased by 5% to $7.9 billion, exceeding analyst expectations [1] - Adjusted EPS was $1.86, higher than the anticipated $1.81 [1] - Sales of HIV-related products rose by 6% to $5.8 billion, driven by increased demand for prevention and treatment [1] - Sales of Remdesivir declined by 37% to $212 million, primarily due to a decrease in COVID-19 related hospitalizations [1] Group 2: Future Outlook - Gilead expects product sales to range between $29.6 billion and $30 billion for the year [1] - The adjusted EPS guidance is projected to be between $8.45 and $8.85, while analysts expect $30.2 billion and $8.75 respectively [1] - The guidance is influenced by a pricing agreement with the Trump administration and uncertainties following the expiration of certain government subsidies [1]

Core Viewpoint - Gilead Sciences reported a 5% year-over-year revenue growth in Q4, reaching $7.9 billion, surpassing analyst expectations of $7.7 billion [1] - The adjusted earnings per share (EPS) were $1.86, exceeding the forecast of $1.81 [1] Financial Performance - Q4 revenue increased to $7.9 billion, up from the previous year [1] - Sales of HIV-related products rose by 6% to $5.8 billion, driven by increased demand for prevention and treatment [1] - Sales of Remdesivir declined by 37% to $212 million, primarily due to a decrease in COVID-19 related hospitalizations [1] Future Outlook - Gilead expects product sales to range between $29.6 billion and $30 billion for the year [1] - The adjusted EPS guidance is projected to be between $8.45 and $8.85, while analysts expect $30.2 billion and $8.75 respectively [1] - The guidance is influenced by a pricing agreement with the Trump administration and uncertainties following the expiration of certain government subsidies [1]

Market Overview - Dow futures rose by 0.10%, S&P 500 futures increased by 0.22%, and Nasdaq futures gained 0.25% [1] Chinese Stocks Performance - Chinese stocks showed mixed results in pre-market trading, with Xpeng Motors up over 2.5%, NIO up over 1.5%, Alibaba down nearly 2%, and JD.com down over 1% [2] Company-Specific News - Firefly Aerospace saw a pre-market drop of over 10%. The company went public this week, with its first-day closing up 34.11%, reaching a market value of approximately $8.5 billion [2] - Gilead Sciences experienced a pre-market increase of nearly 3%. The company reported a 4% year-over-year growth in product sales (excluding remdesivir), totaling $6.9 billion for Q2 2025 [2] - Intel's stock rose nearly 1% after CEO Pat Gelsinger responded to calls from President Trump for his resignation, stating he has full support from the board [2] - Tesla's stock fell by 1.97% as the company reportedly disbanded its Dojo supercomputer team, with plans to rely more on external technology partners like NVIDIA and AMD [2] Technology Developments - Microsoft announced the integration of OpenAI's GPT-5 into its Copilot ecosystem, enhancing reasoning and task-specific responses [3] - TSMC reported a 26% year-over-year revenue growth for July, indicating increased spending by tech companies on artificial intelligence and a rising demand for AI chips [3] Economic Insights - JPMorgan noted that the nomination of Stephen Miran to the Federal Reserve Board by President Trump could increase the likelihood of a rate cut in September [3]